A practical reference on NR1D2: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Agribusiness Arla Foods (dairy) Dansk Landbrugs Grovvareselskab (DLG) (agricultural coop (Danish a.m.b.a.). Main focus is agricultural supply and trade) Danish Crown (meat products) Banking Danske Bank (commercial banking and mortgage lending) Nordea Nykredit Jyske Bank Saxo Bank Sydbank Clothing and attire ECCO (shoe and leather accessories manufacturer and retailer) Bestseller Construction FLSmidth (global supplier of equipment and services to the cement and minerals industries) Rockwool (mineral wool producer with production in 28 countries) Velux (windows and skylights production, owned by Villum Foundation) Rambøll COWI Energy technology Vestas (wind turbines) Siemens Wind Power (wind turbines) Danfoss (climate and energy) Grundfos (the world's largest pump manufacturer) NKT A/S (Power cables and subsea umbilicals) Ørsted (company) (Formerly known as DONG energy) Electronics Linak Bang and Olufsen (hi-fi equipment) Nilfisk Ortofon Danfoss Food and drink Carlsberg (brewing company) Royal Unibrew Novonesis (food ingredients and enzymes) Danisco (enzymes, biotechnology and pharmaceutical supplier) Insurance Alm. Brand Tryg Medical equipment Widex William Demant Pharmaceutical and biotechnology Many of the largest food producers are also engaged in biotechnology and research. Notable companies dedicated to the pharmaceutical and biotechnology sector, includes:
== Applications == HILIC can be applied in many fields including proteomics, metabolomics, medical studies, and agricultural/ food studies, among others. It can be used to separate proteins and peptides, nucleosides, amino acids, sacharides, carbohydrates, and other small, polar, ionizable compounds. HILIC is especially common in metabolomic studies, both for targeted and untargeted approaches, given its ability to retain polar analytes that are poorly suited for traditional reverse-phased columns. This separation technique is also particularly suitable for glycosylation analysis and quality assurance of glycoproteins and glycoforms in biologic medical products. For the detection of polar compounds with the use of electrospray-ionization mass spectrometry as a chromatographic detector, HILIC can offer a ten fold increase in sensitivity over reversed-phase chromatography because the organic solvent is much more volatile. HILIC is considered orthogonal reverse phase chromatography, and these two are increasingly being combined in studies for more comprehensive coverage.
=== 1H—13C HSQC === This experiment provides correlations between a carbon and its attached protons. The constant time (CT) version of 1H—13C HSQC is normally used as it circumvents the issue of splitting of signal due to homonuclear 13C—13C J couplings which reduces spectral resolution. The "constant time" refers to the entire evolution period between the two INEPT steps which is kept constant in this experiment. If this evolution period is set to be the inverse of the J-coupling constant, then the sign of the magnetization of those carbons with an odd number of aliphatic carbon attached will be opposite to those with an even number. For example, if the Cβ of leucine appears as a positive peak (2 aliphatic carbons attached), then the Cγ (3 aliphatic carbons attached) and Cα (1 aliphatic carbons attached) would appear negative.
Sources: en.wikipedia.org
== Retail products == In 2016, the company began offering a canned version of the Draft Latte, a cold-pressed espresso and frothed milk latte which was available on tap in stores. Draft Lattes were initially available in four flavors. The cans for the latte were designed by CEO Todd Carmichael and produced by Crown Holdings. The can employed a valve mechanism at the base for injection of nitrous oxide. Manufacturing of the cans moved from Pennsylvania to a new facility in Norton Shores, Michigan in 2016. A Nitro cold brew was also in the works around 2015. Other products include Different Drum, a coffee-infused rum, produced at a micro-distillery located in its Fishtown, Philadelphia cafe, and a line of La Colombe single-origin and blended roasted coffees, which are available for purchase in retail stores or via the company's website. The company also produces retail cold brew in larger 42oz bottles. In 2020, the company announced a can of instant coffee with new self-heating technology.
== Books and articles == Dobbs, G. Michael (2015). Escape – How Animation Broke into the Mainstream in the 1990s. Orlando: BearManor Media. ISBN 978-1593931100. Finley, Laura L. (2018). Violence in Popular Culture American and Global Perspectives. Santa Monica: ABC-CLIO. ISBN 9781440854330. Komorowski, Thad (2017). Sick Little Monkeys: The Unauthorized Ren & Stimpy Story. Albany, Georgia: BearManor Media. ISBN 978-1629331836.
=== Xen and final release (2015–2020) === The release of the Xen part of the game had been the most difficult, since the team wanted to redesign the levels to overcome the poor perception that they had in Half-Life's original release. The team said, "We want our version of Xen to feel like it really belongs with the rest of the game in terms of mechanics, cohesion and progression," while at the same time, they wanted "to push the boundaries and explore this unique and varied setting; to build an experience that feels both fresh and familiar to players from all walks of Half-Life veterancy." Developing their new version of Xen was a chicken-or-the-egg dilemma, as without level design it was difficult to develop art assets, and without art assets it was hard to come up with cohesive level designs. They also wanted to give more story elements there, such as why human scientists were studying the world of Xen in the first place, trying to capture the same type of world-building by level design that Valve had been able to with the first parts of Half-Life. They also significantly reworked the boss battles to be more challenging and representative of the area they had in mind. Ultimately, the team expanded out Xen from about a one-hour experience in the original Half-Life to four hours in Black Mesa.
Sources: en.wikipedia.org
== History == The first recorded observation of capillary action was by Leonardo da Vinci. A former student of Galileo, Niccolò Aggiunti, was said to have investigated capillary action. In 1660, capillary action was still a novelty to the Irish chemist Robert Boyle, when he reported that "some inquisitive French Men" had observed that when a capillary tube was dipped into water, the water would ascend to "some height in the Pipe". Boyle then reported an experiment in which he dipped a capillary tube into red wine and then subjected the tube to a partial vacuum. He found that the vacuum had no observable influence on the height of the liquid in the capillary, so the behavior of liquids in capillary tubes was due to some phenomenon different from that which governed mercury barometers. Others soon followed Boyle's lead. Some (e.g., Honoré Fabri, Jacob Bernoulli) thought that liquids rose in capillaries because air could not enter capillaries as easily as liquids, so the air pressure was lower inside capillaries. Others (e.g., Isaac Vossius, Giovanni Alfonso Borelli, Louis Carré, Francis Hauksbee, Josia Weitbrecht) thought that the particles of liquid were attracted to each other and to the walls of the capillary. Although experimental studies continued during the 18th century, a successful quantitative treatment of capillary action was not attained until 1805 by two investigators: Thomas Young of the United Kingdom and Pierre-Simon Laplace of France. They derived the Young–Laplace equation of capillary action.
=== Causes === Causes of insufficient vitamin D synthesis in the skin include insufficient exposure to UVB light from sunlight due to living in high latitudes (farther distance from the equator with resultant shorter daylight hours in winter). Serum concentration by the end of winter can be lower by one-third to half that at the end of summer. The prevalence of vitamin D deficiency increases with age due to a decrease in 7-dehydrocholesterol synthesis in the skin and a decline in kidney capacity to convert calcidiol to calcitriol, the latter seen to a greater degree in people with chronic kidney disease. Despite these age effects, elderly people can still synthesize sufficient calcitriol if enough skin is exposed to UVB light. Absent that, a dietary supplement is recommended. Other causes of insufficient synthesis are sunlight being blocked by air pollution, urban/indoor living, long-term hospitalizations and stays in extended care facilities, cultural or religious lifestyle choices that favor sun-blocking clothing, recommendations to use sun-blocking clothing or sunscreen to reduce risk of skin cancer, and lastly, the UV-B blocking nature of dark skin. Consumption of foods that naturally contain vitamin D is rarely sufficient to maintain a recommended serum concentration of 25(OH)D in the absence of the contribution of skin synthesis. Fractional contributions are roughly 20% diet and 80% sunlight.
agencies like the DEA, underscored the necessity of international cooperation, intelligence-sharing, and advanced surveillance technologies, while also exposing the limitations of militarized approaches in addressing the socio-economic drivers of the drug trade. Guzmán's high-profile status and the Sinaloa Cartel's global reach made his capture a symbolic victory, yet it also revealed the resilience of drug trafficking networks, as the cartel continued operations unabated, reflecting the broader, ongoing struggle to dismantle such organizations in the global anti-drug campaign. The Mérida Initiative, launched in 2008, was a security cooperation program between the US and Mexico, aimed at combating drug trafficking and transnational crime. From 2008 to 2021, the US provided $3.5 billion in funding. The initial focus was anti-drug and rule-of-law measures, later broadened to include US-Mexico border activities. Components included military and law enforcement training and equipment, and technical advice and training to strengthen the national justice systems. In 2021, it was replaced by the Bicentennial Framework for Security, Public Health, and Safe Communities. In 2013, a Pew Research Center poll found that 85% of Mexican citizens supported using the Mexican army against drug cartels, 74% supported US training assistance for their police and military, 55% supported the US supplying of weapons and financial aid, and 59% were against deploying US troops on Mexican soil.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.